BioSpace News Archive

Neurim’s PedPRM, targeted to treat sleep disorders in children with autism spectrum disordersand neurogenetic diseases, is expected to be the first sleep drug approved for children.

As per a new World Bank/IFC-funded study by MobileODT and Apollo Hospitals, deploying the EVA System at primary cervical cancer screenings leads to a higher detection rate of suspected precancerous and cancerous lesions for women in both urban and rural areas, than a pap smear alone.

Intrexon announced today that it has priced its previously announced underwritten public offering of common stock consisting of 6,000,000 shares at a public offering price of $12.50 per share.

ENG’s mobile labs represent the fastest growing segment of ENG’s specialty vehicle business.

These data will be presented at the 2018 ASCO GI in San Francisco, California.

BD announced today that it will host a live webcast of its Annual Meeting of Shareholders on Tuesday, January 23, 2018, at 1 p.m.

These new patents add to the over 800 issued or pending patents worldwide and address many of BioTime’s key programs, including OpRegen.

This new aqueous system delivers a more streamlined application process, reducing coating time from days to hours and improving manufacturing safety through the elimination of organic solvents.

Osel, Inc. today announced the first patient has been dosed in a new clinical study launched in collaboration with five Danish fertility clinics and Statens Serum Institute to determine whether LACTIN-V can improve the success rate of in vitro fertilization (IVF) for infertile women with abnormal vaginal microbiota (AVM).

Regen BioPharma (OTCQB: RGBP) and (OTCQB: RGBPP) continues to develop small molecule drugs that activate NR2F6 and has identified a key structural element whose presence in small molecules seems to be required for activation of NR2F6.